---
title: "Duality Biotherapeutics Reshapes Board and Finance Leadership to Back R&D Strategy"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/280163147.md"
description: "Duality Biotherapeutics, Inc. has announced significant changes to its board and finance leadership effective March 23, 2026. Executive director Si Wen will resign, while Hua Haiqing is appointed as executive director and Zhang Shaoren as CFO. This restructuring aims to enhance governance and financial oversight to support the company's drug development strategy. The recent analyst rating for Duality Biotherapeutics (HK:9606) is a Buy with a price target of HK$493.00, reflecting confidence in the company's growth potential in the biotech sector."
datetime: "2026-03-23T12:37:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280163147.md)
  - [en](https://longbridge.com/en/news/280163147.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280163147.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/280163147.md) | [English](https://longbridge.com/en/news/280163147.md)


# Duality Biotherapeutics Reshapes Board and Finance Leadership to Back R&D Strategy

### Claim 30% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Duality Biotherapeutics, Inc. ( (HK:9606) ) has shared an announcement.

Duality Biotherapeutics has announced a series of senior management and board changes effective March 23, 2026, including the resignation of executive director Si Wen from the board and the remuneration committee for personal career reasons, while she continues to lead human resources. The company has simultaneously appointed long-time R&D leader Hua Haiqing as an executive director, named Zhang Shaoren as chief financial officer, and added Zhu Zhongyuan to the remuneration committee, signaling a reconfiguration of governance and financial leadership to support its drug development strategy.

Hua, who has nearly 15 years of drug discovery experience at international and Chinese pharmaceutical organizations and has led the group’s pipeline and R&D strategy since 2021, will serve a three-year term as executive director under an appointment letter and receive compensation linked to his broader role in the group. The reshuffle aligns experienced scientific and financial executives more closely with the board and key committees, potentially strengthening oversight of R&D investment, capital allocation and incentive structures as Duality Biotherapeutics advances its pipeline in a competitive biotech landscape.

The most recent analyst rating on (HK:9606) stock is a Buy with a HK$493.00 price target. To see the full list of analyst forecasts on Duality Biotherapeutics, Inc. stock, see the HK:9606 Stock Forecast page.

**More about Duality Biotherapeutics, Inc.**

Duality Biotherapeutics, Inc. is a biopharmaceutical company focused on drug discovery and development, operating through a group structure with subsidiaries. The company develops new drugs and therapeutic pipelines, targeting innovative R&D-driven growth in the global healthcare and life sciences markets.

**Average Trading Volume:** 736,438

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** HK$25.26B

### 相關股票

- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-HK/quote/159837.CN.md)
- [Sensei Biotherapeutics (SNSE.US)](https://longbridge.com/zh-HK/quote/SNSE.US.md)
- [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/zh-HK/quote/588860.CN.md)
- [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-HK/quote/159849.CN.md)
- [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-HK/quote/159992.CN.md)
- [Sutro Biopharma (STRO.US)](https://longbridge.com/zh-HK/quote/STRO.US.md)
- [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/zh-HK/quote/520690.CN.md)
- [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-HK/quote/516500.CN.md)
- [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/zh-HK/quote/159859.CN.md)
- [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/zh-HK/quote/516820.CN.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/zh-HK/quote/520880.CN.md)
- [Direxion S&P Biotech Bull 3X (LABU.US)](https://longbridge.com/zh-HK/quote/LABU.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-HK/quote/516930.CN.md)
- [DUALITYBIO-B (09606.HK)](https://longbridge.com/zh-HK/quote/09606.HK.md)
- [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/zh-HK/quote/560600.CN.md)
- [Atara Biotherap (ATRA.US)](https://longbridge.com/zh-HK/quote/ATRA.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-HK/quote/510660.CN.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-HK/quote/588130.CN.md)
- [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/zh-HK/quote/159316.CN.md)
- [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-HK/quote/512010.CN.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/zh-HK/quote/588250.CN.md)
- [Bioxcel Therap (BTAI.US)](https://longbridge.com/zh-HK/quote/BTAI.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-HK/quote/512290.CN.md)
- [Unity Biotechnology (UBX.US)](https://longbridge.com/zh-HK/quote/UBX.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)

## 相關資訊與研究

- [Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update | SNSE Stock News](https://longbridge.com/zh-HK/news/281009876.md)
- [BioXcel says FDA accepts IGALMI sNDA for at-home agitation treatment](https://longbridge.com/zh-HK/news/281352484.md)
- [Telomir seeks FDA approval for Telomir-1 to treat breast cancer](https://longbridge.com/zh-HK/news/281346305.md)
- [Vertex wins FDA label expansion for Alyftrek cystic fibrosis treatment in ages 6+](https://longbridge.com/zh-HK/news/281358299.md)
- [BUZZ-Cyclerion rises on merger with Korsana Biosciences, $380 mln funding](https://longbridge.com/zh-HK/news/281356162.md)